Sophie McGrath

2.4k total citations
26 papers, 337 citations indexed

About

Sophie McGrath is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sophie McGrath has authored 26 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Sophie McGrath's work include HER2/EGFR in Cancer Research (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sophie McGrath is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sophie McGrath collaborates with scholars based in United Kingdom, Netherlands and Italy. Sophie McGrath's co-authors include Richard Morgan, Hardev Pandha, Agnieszka Michael, Philip Savage, Richard Harvey, Michael J. Seckl, D Short, Peter Schmid, Alistair Ring and Thumuluru Kavitha Madhuri and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sophie McGrath

23 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sophie McGrath United Kingdom 12 120 102 85 75 72 26 337
Alessia Romito Italy 11 118 1.0× 98 1.0× 78 0.9× 55 0.7× 64 0.9× 19 394
Nidale Tarek United States 11 170 1.4× 120 1.2× 61 0.7× 68 0.9× 30 0.4× 27 479
Nor Haslinda Abd Aziz Malaysia 11 168 1.4× 86 0.8× 36 0.4× 23 0.3× 50 0.7× 27 426
Audrey P. Garrett United States 9 77 0.6× 72 0.7× 84 1.0× 61 0.8× 49 0.7× 15 467
Charlotte Maggen Belgium 11 321 2.7× 84 0.8× 54 0.6× 161 2.1× 52 0.7× 23 419
Monika Pogorzała Poland 12 53 0.4× 82 0.8× 84 1.0× 73 1.0× 32 0.4× 32 341
Joanna Zawitkowska Poland 11 115 1.0× 126 1.2× 173 2.0× 92 1.2× 34 0.5× 61 386
Bachar Samra United States 9 136 1.1× 97 1.0× 113 1.3× 23 0.3× 32 0.4× 18 364
Satyajit Kosuri United States 12 150 1.3× 128 1.3× 73 0.9× 22 0.3× 25 0.3× 47 420
Aubrey K. Hubbard United States 8 46 0.4× 86 0.8× 46 0.5× 49 0.7× 41 0.6× 18 248

Countries citing papers authored by Sophie McGrath

Since Specialization
Citations

This map shows the geographic impact of Sophie McGrath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie McGrath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie McGrath more than expected).

Fields of papers citing papers by Sophie McGrath

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophie McGrath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie McGrath. The network helps show where Sophie McGrath may publish in the future.

Co-authorship network of co-authors of Sophie McGrath

This figure shows the co-authorship network connecting the top 25 collaborators of Sophie McGrath. A scholar is included among the top collaborators of Sophie McGrath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophie McGrath. Sophie McGrath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tommasi, Chiara, Nalinie Joharatnam‐Hogan, Benedetta Pellegrino, et al.. (2024). The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study. Breast Cancer Research and Treatment. 206(3). 603–614. 2 indexed citations
3.
4.
Husson, Olga, Emma Hainsworth, Emma Lidington, et al.. (2024). Evaluating a digital tool for supporting people affected by breast cancer: a prospective randomized controlled trial—the ADAPT study. Supportive Care in Cancer. 32(11). 740–740. 2 indexed citations
5.
Shepherd, Scott T.C., Kabir Mohammed, Karla A. Lee, et al.. (2022). Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital. Breast Cancer Research and Treatment. 195(3). 333–340. 5 indexed citations
6.
Downey, Kate, et al.. (2022). Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer. Cancer Treatment and Research Communications. 31. 100548–100548. 6 indexed citations
7.
Bhaludin, Basrull, Nina Tunariu, Dow‐Mu Koh, et al.. (2022). A review on the added value of whole-body MRI in metastatic lobular breast cancer. European Radiology. 32(9). 6514–6525. 9 indexed citations
8.
Bhaludin, Basrull, Nina Tunariu, Neil Soneji, et al.. (2022). Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?. Cancer Imaging. 22(1). 26–26. 3 indexed citations
9.
Angelis, Vasileios, et al.. (2021). 97P Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK cancer centre experience. Annals of Oncology. 32. S64–S65. 1 indexed citations
10.
Battisti, Nicolò Matteo Luca, Karla Lee, Scott T.C. Shepherd, et al.. (2020). Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. Cancer Treatment and Research Communications. 24. 100188–100188. 16 indexed citations
11.
Angelis, Vasileios, Zayd Tippu, Kroopa Joshi, et al.. (2020). Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. European Journal of Cancer. 136. 99–106. 21 indexed citations
12.
Lidington, Emma, Sophie McGrath, Jillian Noble, et al.. (2020). Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT). Trials. 21(1). 86–86. 11 indexed citations
13.
Battisti, Nicolò Matteo Luca, Neha Chopra, Karla Lee, et al.. (2019). Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. Breast Cancer Research and Treatment. 179(1). 101–111. 17 indexed citations
14.
McGrath, Sophie, Nicola Annels, Thumuluru Kavitha Madhuri, et al.. (2018). Engrailed-2 (EN2) – a novel biomarker in epithelial ovarian cancer. BMC Cancer. 18(1). 943–943. 24 indexed citations
15.
Annels, Nicola, Guy R. Simpson, M. Denyer, et al.. (2014). Spontaneous antibodies against Engrailed-2 (EN2) protein in patients with prostate cancer. Clinical & Experimental Immunology. 177(2). 428–438. 3 indexed citations
16.
McGrath, Sophie, Agnieszka Michael, Hardev Pandha, & Richard Morgan. (2013). Engrailed homeobox transcription factors as potential markers and targets in cancer. FEBS Letters. 587(6). 549–554. 20 indexed citations
17.
McGrath, Sophie, Andrew Webb, & Karen Walker‐Bone. (2012). Bleomycin-Induced Raynaud's Phenomenon After Single-Dose Exposure: Risk Factors and Treatment With Intravenous Iloprost Infusion. Journal of Clinical Oncology. 31(4). e51–e52. 17 indexed citations
18.
McGrath, Sophie, et al.. (2012). Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors: a review of patients at Charing Cross Hospital, 2000-2009.. PubMed. 57(7-8). 319–24. 15 indexed citations
19.
McGrath, Sophie, D Short, Richard Harvey, et al.. (2010). The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l−1. British Journal of Cancer. 102(5). 810–814. 64 indexed citations
20.
McGrath, Sophie & Alistair Ring. (2010). Chemotherapy for breast cancer in pregnancy: evidence and guidance for oncologists. Therapeutic Advances in Medical Oncology. 3(2). 73–83. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessia Romito Breakdown of academic impact, for papers by Nidale Tarek Breakdown of academic impact, for papers by Nor Haslinda Abd Aziz Breakdown of academic impact, for papers by Audrey P. Garrett Breakdown of academic impact, for papers by Charlotte Maggen Breakdown of academic impact, for papers by Monika Pogorzała Breakdown of academic impact, for papers by Joanna Zawitkowska Breakdown of academic impact, for papers by Bachar Samra Breakdown of academic impact, for papers by Satyajit Kosuri Breakdown of academic impact, for papers by Aubrey K. Hubbard
Rankless by CCL
2026